本文へ移動
cccskills
無料GitHub で公開

es-cushing-late-night-cortisol-measurement-post-tss

This skill recommends measuring late-night salivary or serum cortisol to screen for Cushing's disease recurrence in patients with eucortisolism after transsphenoidal surgery, including cases where eucortisolism was established by medical treatment prior to surgery. Use when postoperative follow-up shows eucortisolism (normal morning cortisol/UFC) but concern for recurrence exists.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Measuring Late-Night Salivary or Serum Cortisol in Patients with Eucortisolism After TSS

STEP 1 — Gather Information

Collect postoperative morning serum cortisol and/or UFC, medication list (especially glucocorticoids), timing of transsphenoidal surgery, and any symptoms suggestive of recurrence (e.g., weight gain, hypertension, hyperglycemia). Confirm eucortisolism (normal morning cortisol and UFC) and absence of exogenous glucocorticoids.

STEP 2 — Rule In / Rule Out

If morning cortisol or UFC is elevated (not eucortisolemic) → manage persistent hypercortisolism per guideline; if morning cortisol and UFC are normal (eucortisolemic) → proceed to measure late-night cortisol.

STEP 3 — Classify or Stratify

If late-night salivary or serum cortisol is within the laboratory’s reference range → classify as likely remission; if late-night cortisol is above the reference range → classify as suspicious for recurrence.

STEP 4 — Decide

For likely remission → continue routine surveillance with clinical assessment and periodic morning cortisol/UFC every 6–12 months; for suspicious recurrence → repeat late-night cortisol, obtain UFC, and perform pituitary MRI; consider referral for re-intervention (repeat TSS, medical therapy, or radiation).

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on morning cortisol/UFC to exclude recurrence; do not measure late-night cortisol while patient is on exogenous glucocorticoids; avoid interpreting a single borderline result without repeat testing under standardized conditions; do not use late-night cortisol in patients with irregular sleep schedules or shift work without adjusting sample timing; do not base treatment decisions on late-night cortisol alone without correlating with clinical symptoms and other biochemical tests.

Concrete Clinical Example

A 48‑year‑old woman had TSS for Cushing disease. At 5‑month postoperative visit, morning serum cortisol and UFC were normal, she was asymptomatic, and not on glucocorticoids. A late‑night salivary cortisol drawn at 11 PM was within normal limits, supporting remission; she continued routine follow‑up. In another case, a similar patient had an elevated late‑night salivary cortisol, prompting repeat UFC and MRI, which revealed a residual adenoma requiring repeat TSS.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する